The company has changed its management to appoint a deputy general manager, and the company has changed several times since its listing

【Pharmaceutical Network Enterprise News】On October 25, 2022, Luyan Pharmaceutical announced that upon nomination by the general manager of the company, the company agreed to appoint Mr.
Wu Di as the deputy general manager
of the company.
According to the resume, Wu Di, male, born in 1991, Chinese nationality, has the right of permanent residence in Canada, graduated from the Ivey Business School of Weston University in Canada in 2014 with a master's degree
in management.
He is currently the director, assistant to the president and general manager of the retail business department, and director of
Xiamen Medican Technology Co.
, Ltd.
, Xiamen Sanstate Technology Co.
, Ltd.
and Xiamen Luyan Biotechnology Co.
, Ltd 。 As of the disclosure date of this announcement, Mr.
Wu Di does not hold shares in the Company, and Mr.
Wu Di is related to Mr.
Wu Jinxiang, the actual controller of the Company, the chairman and general manager of the Company, is the son of Mr.
Wu Jinxiang, has no affiliation with other directors, supervisors and senior management, does not have the circumstances stipulated in the Company Law and the Articles of Association of the Company and is not allowed to serve as a senior management of the Company, and has not been punished or disciplined
by the China Securities Regulatory Commission and the Shenzhen Stock Exchange 。 According to the data, Luyan Pharmaceutical's main business is the distribution of medicines, Chinese medicine pieces, medical devices and pharmaceutical retail chains, and the main source of income is pharmaceutical wholesale sales revenue
.
The company's initial public offering of A shares was successfully listed
on the SME board of the Shenzhen Stock Exchange on February 18, 2016.
It is understood that the company has changed a number of deputy general managers
since its listing.
For example, on May 29, 2021, Luyan Pharmaceutical issued an announcement that the company's board of directors received a written resignation report submitted by Mr.
Zhao Zhongming, deputy general manager of the company, on May 28, 2021, Mr.
Zhao Zhongming requested to resign from the position of deputy general manager of the company for personal reasons, and after his resignation, Mr.
Zhao Zhongming will no longer hold any other position in the company except for continuing to serve as a director of Fujian Kangyuan Image Intelligence Research Institute, a non-profit organization initiated by the company, and a director of Guangzhou Kangyuan Image Intelligence Research Institute
。 As at the disclosure date of this announcement, Mr.
Zhao Zhongming does not hold any shares in
the Company.
Zhao Zhongming's relevant resume shows that from 1989 to 2004, he worked in the Information Center of Guangzhou Economic and Technological Development Zone (Luogang District, Guangzhou City), successively serving as an engineer, senior engineer, chief engineer, and deputy general manager of Weconcom Information Network Company in Guangzhou Development Zone; From 2004 to August 2016, he successively served as the director of Guangzhou Panyu District Information Office, the director of Guangzhou Panyu District Government Management Office, and the director of Guangzhou Panyu District Information Center
.
In July 2017, Luyan Pharmaceutical announced that the board of directors of the company recently received a written resignation report submitted by Mr.
Zheng Chongbin, deputy general manager, Mr.
Zheng Chongbin submitted to resign from the position of deputy general manager of the company due to retirement at age, and Mr.
Zheng Chongbin will serve as an advisor to
the company after his resignation.
Behind the change of executives, the company's business is also constantly escalating
.
Since 2018, Luyan Group has reached a new level of development, and has successively established five major business units, including Traditional Chinese Medicine and Medical Care Division, New Business Format Division, Pharmaceutical Distribution Division, Retail Division, and Equipment Division, to jointly promote the rapid development of
the Group's various businesses.
It is reported that Luyan Pharmaceutical actively extends to the upstream and downstream of the industrial chain of R&D and manufacturing, medical treatment, elderly care, health care, etc.
, builds a large health ecosystem, and strives to contribute
to the development of human health industry.
According to the 2021 annual report, the company achieved total operating income of 17.
55 billion yuan in 2021, a year-on-year increase of 12.
9%; The net profit attributable to the parent was 310 million yuan, a year-on-year increase of 14.
7%; Earnings per share were $0.
79
.
According to the third quarter of 2022 results announcement, the company's revenue in the first three quarters of 2022 was about 14.
324 billion yuan, a year-on-year increase of 10.
16%; the net profit attributable to shareholders of listed companies was about 251 million yuan, an increase of 8.
04% over the same period last year; Basic earnings per share were 0.
65 yuan, an increase of 8.
33%
over the same period last year.
Disclaimer: Under no circumstances does the information or opinions expressed in this article constitute investment advice
to anyone.